Dr. Woldu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-8765Fax+1 214-645-8769- Is this information wrong?
Summary
- Dr. Solomon Woldu is an urologist in Dallas, TX and is affiliated with multiple hospitals in the area, including William P. Clements, Jr. University Hospital, Parkland Health & Hospital System, JPS Health Network, and Veterans Affairs North Texas Health Care System. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 7 years. He specializes in surgical oncology and is experienced in urology and urologic neoplasms.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Minimally Invasive Urologic Surgery, 2016 - 2018
New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 2011 - 2016- New York Presbyterian HospitalInternship, Transitional Year, 2010 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2010
Washington University in St. LouisB.A., Biology, 2002 - 2006
Certifications & Licensure
TX State Medical License 2016 - 2025- American Board of Urology Urology
Clinical Trials
- Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer Start of enrollment: 2021 Sep 06
- Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma Start of enrollment: 2021 Nov 29
Publications & Presentations
PubMed
- Impact of pathologic features on local recurrence in penile squamous cell carcinoma after penectomy.Eshan Joshi, Thomas Gerald, Samuel A Gold, Solomon L Woldu, Xiaosong Meng, Aditya Bagrodia, Kris Gaston, Vitaly Margulis> ;Surgical Oncology. 2024 Mar 19
- Reply to Khurshid R. Ghani's letter to editor regarding the article "Early experience with UGN-101 for the treatment of upper tract urothelial cancer: a multicenter ev...Solomon Woldu, Yair Lotan> ;Urologic Oncology. 2024 Mar 1
- Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.Lee, B., Smith, A., Lotan, Y., Agarwal, P., Black, P., Dickstein, R., Kamat, A., Narayan, V., Porten, S., Psutka, S., Svatek, R., Williams, S., Woldu, S.> ;Urologic Oncology. 2024 Feb 1
- Join now to see all
Authored Content
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Press Mentions
UTSW-Led Study Shows Promise for Drug to Treat Upper Urinary Tract CancersJanuary 3rd, 2023
Grant Support
- T32 GrantNational Institute of Health2016–2018
Hospital Affiliations
William P. Clements, Jr. University HospitalDallas, Texas
Parkland HealthDallas, Texas
JPS Health NetworkFort Worth, Texas
Dallas VA North Texas HCSDallas, Texas
University of Texas Southwestern Medical CenterDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
